Abstract
Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not been identified. Combinations of a 5-HT3 antagonist and dexamethasone show increased efficacy with respect to 5-HT3 antagonists alone. All pediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819
Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994
Komada Y, Matsuyama T, Takao A, et al (1999) A randomised dose-comparison trial of granisetron in preventing emesis in children with leukemia receiving emetogenic chemotherapy. Eur J Cancer 35:1095–1101
Koseoglu V, Kurekci AE, Sarici U, et al (1998) Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 157:806–810
Mabro M, Cohn R, Zanesco L, et al (2000) Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of two doses. Bull Cancer 87:259–264
Roila F, Aapro M, Stewart A (1998) Optimal selection of antiemetics in children receiving cancer chemotherapy. Support Care Cancer 6:215–220
Sandoval C, Corbi D, Strobino B, et al (1999) Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 17:309–313
Small BE, Holdsworth MT, Raisch DW, et al (2000) Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 22:125–132
Stiakaki E, Savvas S, Lydaki E, et al (1999) Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 16:101–108
White L, Dally SA, McKenna CJ, et al (2000) A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 17:445–455
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00520-005-0777-8
Rights and permissions
About this article
Cite this article
Roila, F., Feyer, P., Maranzano, E. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 13, 129–131 (2005). https://doi.org/10.1007/s00520-004-0702-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0702-6